CanSino Biologics Inc. (the “Company,” stock code: 6185) has officially initiated a Phase I clinical trial for its inhaled tuberculosis vaccine (Adenovirus Type 5 Vector), referred to as the inhaled TB Booster. The first trial patient for this inhaled TB Booster trial in Indonesia has been enrolled.

Current preventive measures for tuberculosis primarily rely on Bacillus Calmette-Guerin (BCG), which is widely used worldwide, especially for infants and children. However, BCG’s efficacy diminishes over time. To address this, the Company has developed a globally innovative TB Booster for BCG-vaccinated populations, with previous Phase Ia and Phase Ib trials conducted in Canada demonstrating its safety and efficacy. Building on its existing inhalation technology platform, the Company has upgraded the product by delivering it via aerosol inhalation, aiming to stimulate an immune response in the lungs more effectively.

The newly launched Phase I clinical trial in Indonesia involves participants aged 18 to 49, focusing on the safety and immunogenicity of a single-dose inhaled TB Booster. According to the announcement dated November 13, 2025, shareholders and potential investors are advised to exercise caution when dealing in the Company’s shares.